provider portal
Wesper Journal
This article explores how oral GLP-1 therapy, specifically Eli Lilly’s investigational pill orforglipron, may transform the treatment of obstructive sleep apnea (OSA) by targeting one of its primary root causes: obesity. It highlights clinical evidence from GLP-1 drugs like tirzepatide (Zepbound), which has already gained FDA approval for OSA, and examines how weight loss through these therapies significantly improves apnea severity. The article also outlines why the upcoming oral formulation is a game-changer, increasing accessibility and adherence for patients. With obesity, diabetes, and OSA deeply intertwined, GLP-1 therapy may soon play a central role in holistic sleep medicine.
Continue reading
When insomnia threatens your career, prioritizing sleep hygiene and seeking professional support can enhance work performance and overall well-being. Effective sleep management strategies, such as maintaining a consistent sleep schedule and utilizing sleep tracking technology, are crucial for balancing sleep...
Continue reading
In choosing between home sleep tests and lab studies, consider home tests for affordable, convenient diagnosis of sleep apnea, and opt for lab studies for comprehensive analysis if complex sleep disorders or additional health conditions exist. Consult a healthcare professional...
Continue reading
Sleep apnea in your 20s, characterized by symptoms like loud snoring, excessive fatigue, and difficulty concentrating, can significantly disrupt daily life and health. Early diagnosis and exploring treatment options such as CPAP, oral appliances, and lifestyle changes, alongside leveraging healthcare...
Continue reading
Sleep apnea can lead to dizziness through low blood oxygen levels, impaired blood flow to the inner ear, and cerebrovascular issues. Addressing sleep apnea with treatments like CPAP therapy may alleviate dizziness and improve overall health. The Connection Between Sleep...
Continue reading